Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization-Reference-Cited by-同舟云学术

Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization

Published:2022-06 Issue: Volume:77 Page:1-15
ISSN:1045-1056
Container-title:Biologicals
language:en
Short-container-title:Biologicals

Author:

Ruppen Isabel,Beydon Marie-Elise^ORCID,Solís Clea,Sacristán Daniel,Vandenheede Isabel,Ortiz Alexia,Sandra Koen,Adhikary Laxmi

Publisher

Elsevier BV

Subject

Pharmacology,General Immunology and Microbiology,Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Reference69 articles.

1. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture;Harris;J Chromatogr A,1995

2. Heterogeneity of recombinant antibodies: linking structure to function;Harris;Dev Biol,2005

3. Identification of multiple sources of charge heterogeneity in a recombinant antibody;Harris;J Chromatogr B Biomed Sci Appl,2001

4. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS;Huang;Anal Chem,2005

5. Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody;Chumsae;J Chromatogr B Analyt Technol Biomed Life Sci,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-Depth Characterization for Methionine Oxidization in Complementary Domain Region by Hydrophobic Interaction Chromatography;ACS Pharmacology & Translational Science;2024-07-18

2. Characterization of mAb size heterogeneity originating from a cysteine to tyrosine substitution using denaturing and native LC-MS;Journal of Pharmaceutical and Biomedical Analysis;2023-11

3. In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma;Animals;2023-08-03

4. A Review of the Non-clinical and Clinical Requirements for the performance of a comparability exercise for Bevacizumab biosimilars;Research Journal of Pharmacy and Technology;2023-07-24

5. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes;Analytical and Bioanalytical Chemistry;2023-05-10